Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Role of Innate Immunity in Colorectal Cancer

  • Bora Keum (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine)
  • Received : 2018.06.10
  • Accepted : 2018.06.11
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Chemotherapy and surgical resection are the mainstay of cancer treatment. Particularly for chemotherapy, although it is effective method to care, sometimes cure various cancers, there are many different status of cancer not being controlled by chemotherapy such as recurrence and resistance to chemotherapy. In order to overcome those difficulties during cancer therapy, immunotherapy targeting immune cells and immune associated factors to enhance cancer immunity has been highlighted. Innate immunity plays important roles on initial stage of cancer immunity that are detecting, killing cancer cells and initiating adaptive immunity for cancer. So many basic and clinical studies to manage innate immunity for cancer therapy have been going on, and most of them were to stimulate innate immune cells including dendritic cell, macrophage, monocyte, and natural killer cell in various ways. They showed promising results but still there are many things to be resolved before clinical application. Herein, I review the role of innate immune cells and therapeutic trials for colorectal cancer.

Keywords

References

  1. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012;72:3125-3130.
  2. Striz I, Brabcova E, Kolesar L, et al. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci (Lond) 2014;126:593-612.
  3. Legitimo A, Consolini R, Failli A, et al. Dendritic cell defects in the colorectal cancer. Hum Vaccin Immunother 2014;10:3224-3235.
  4. Gulubova MV, Ananiev JR, Vlaykova TI, et al. Role of dendritic cells in progression and clinical outcome of colon cancer. Int J Colorectal Dis 2012;27:159-169.
  5. Orsini G, Legitimo A, Failli A, et al. Quantification of blood dendritic cells in colorectal cancer patients during the course of disease. Pathol Oncol Res 2014;20:267-276.
  6. Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013;258:879-886.
  7. Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14:399-416.
  8. Bogels M, Braster R, Nijland PG, et al. Carcinoma origin dictates differential skewing of monocyte function. Oncoimmunology 2012;1:798-809.
  9. Roslyn Kemp SN, Edward Taylor, Elliott Dunn, Fran Munro, Michael Black and John McCall. Colorectal tumoru associated macrophages are more pro-inflammatory than adjacent control bowel tissue macrophage populations (TUM6P.1003). J Immunol 2015;194(1 Supplement):1.
  10. Cavnar MJ, Turcotte S, Katz SC, et al. Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. Ann Surg Oncol 2017;24:1835-1842.
  11. Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 2013;3:49.
  12. Inamoto S, Itatani Y, Yamamoto T, et al. Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis. Clin Cancer Res 2016;22:492-501.
  13. Qin H, Lerman B, Sakamaki I, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 2014;20:676-681.
  14. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2016;16:7-19.
  15. Jobin G, Rodriguez-Suarez R, Betito K. Association Between Natural Killer Cell Activity and Colorectal Cancer in High-Risk Subjects Undergoing Colonoscopy. Gastroenterology 2017;153:980-987.